Published by Alexander Bueso on 1st August 2017
(ShareCast News) - Analysts at Jefferies cut their target price for AstraZeneca's shares following various updates from the company, especially as regards its MYSTIC clinical trial for its anti-lung cancer tumour treatment Imfinzi.
URL: http://www.digitallook.com/dl/news/story/26259437/...